How is a percutaneous core needle biopsy performed in a pediatric patient with a urinary bladder mass?

Percutaneous Core Needle Biopsy for Pediatric Urinary Bladder Mass

Percutaneous core needle biopsy of a bladder mass in a pediatric patient is performed using image guidance (CT or ultrasound), typically with a coaxial 17-18 gauge core biopsy system, via a transabdominal or transgluteal approach depending on tumor location, and is a safe alternative to transurethral resection when the latter is not feasible.

Technical Approach

Image Guidance Selection

• CT guidance is preferred (used in 88.1% of cases) for precise needle placement and visualization of surrounding structures 1
• Ultrasound guidance is an acceptable alternative, particularly for anterior or dome lesions, and has proven safe and effective in pediatric abdominal/pelvic masses 2

Needle Selection and Technique

• Use 17-18 gauge coaxial core biopsy systems (standard in 84.7% of procedures) 1
• Large-bore needles provide adequate tissue for histopathologic diagnosis and molecular/cytogenetic analysis without requiring general anesthesia 3
• Multiple cores should be obtained to ensure sufficient tissue, as inadequate sampling occurred in 3.5% of malignant cases for complete diagnosis 2

Access Route Planning

The approach depends on tumor location within the bladder:

For anterior, superior, or lateral bladder wall lesions:

• Transabdominal approach through the lower anterior abdominal wall 4
• This is the classical route but may require traversing the peritoneum

For posterior, presacral, or bladder base lesions:

• Transgluteal approach provides safe extraperitoneal access 4
• Useful for masses posterolateral to the bladder

For lateral pelvic wall or difficult-to-access lesions:

• Anterolateral approach through the iliopsoas muscle allows extraperitoneal access 4
• Consider transosseous (transsacral or transiliac) routes for otherwise inaccessible lesions 4

Technical modifications when needed:

• Use curved needles to navigate around vital structures
• Reposition the patient to optimize access
• Inject saline to displace intervening bowel or vessels 4

Procedural Considerations

Pre-procedure imaging:

• CT or MRI of abdomen/pelvis should be obtained before biopsy to characterize the lesion and plan the safest trajectory 5, 6, 7
• Assess for hydronephrosis, lymphadenopathy, and relationship to adjacent organs

Anesthesia:

• General anesthesia is not required for most pediatric patients undergoing percutaneous biopsy 3
• Conscious sedation is typically sufficient

Marker placement:

• Consider placing a marker clip at the biopsy site for future localization if neoadjuvant therapy is planned 8

Diagnostic Yield and Safety

Efficacy

• Diagnostic accuracy: 94.9-98.8% for malignant lesions 1, 2
• Technical success rate approaches 100% 1, 3
• Concordance with subsequent surgical pathology: 92.9% 1
• Typing accuracy: 100% for malignant disease, 92-100% for benign lesions 2, 3

Safety Profile

• No severe adverse events or procedure-related mortality reported in pediatric series 1, 2, 3
• Minor complications (5-13% of cases):
  • Mild pain (2 patients) 2
  • Self-limited bleeding from biopsy site (2 patients) 2
  • Minor urinary tract infections (2 cases) 1
  • Wound infection (1 patient) 2
• Moderate complications requiring treatment: bleeding events in 3.4% 1

Clinical Context and Indications

When to consider percutaneous biopsy over transurethral resection:

• Transurethral resection not feasible due to patient frailty or comorbidities 1
• Submucosal masses without mucosal abnormality on cystoscopy 9
• Need for tissue diagnosis before initiating neoadjuvant chemotherapy 3
• Suspected non-urothelial histology requiring specific molecular/cytogenetic analysis 2

Important caveats:

• Bladder tumors in children are extremely rare; rhabdomyosarcoma is the most common malignant bladder tumor in pediatric patients, not urothelial carcinoma 10
• Standard diagnostic approach remains cystoscopy with transurethral resection when feasible 11, 5, 6, 12, 7
• Percutaneous biopsy should be reserved for cases where transurethral approach is contraindicated or technically impossible
• Ensure adequate tissue is obtained for both histopathology and molecular studies, as 3.5% of cases may be inadequate for complete cytogenetic analysis 2